

EXECUTIVE AGENCY
FISCAL NOTE

AGENCY'S ESTIMATES

Date Prepared: April 7, 2021

Agency Submitting: Department of Health and Human Services

Items of Revenue or Expense, or Both	Fiscal Year 2020-21	Fiscal Year 2021-22	Fiscal Year 2022-23	Effect on Future Biennia
Total	0	0	0	0

Explanation

(Use Additional Sheets of Attachments, if required)

The Department of Health and Human Services has reviewed this bill and cannot determine a fiscal impact.

As currently written, the department believes its current Drug Transparency database will not meet the requirements of SB 380, nor can it be modified to do so; therefore, it is likely that an electronic database will be required. Additionally, according to security researchers at securityscorecard.com, pharmaceutical related applications are believed to be huge ransomware targets and have become a major target by hacking groups with the COVID-19 vaccine rollout that may require additional security protocols. Until a database is selected or created, the department cannot determine its costs or if additional staff will be needed.

Section 8 allows the department to audit the records of manufacturers, pharmacy benefit managers, wholesalers, third parties or nonprofit organizations. Until more information is received, it is unknown if the audit function will be required or to what degree.

Name Mark Winebarger

Title ASO 4

GOVERNOR'S OFFICE OF FINANCE COMMENTS

The agency's response appears reasonable.

Date Tuesday, April 06, 2021

Name Bessie J. Wooldridge

Title Executive Branch Budget Officer